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ABSTRACT
Background: Cocoa flavanol intake, especially that of (2)-epicatechin,
has been linked to beneficial effects on human cardiovascular func-
tion. However, cocoa also contains the methylxanthines theobro-
mine and caffeine, which may also affect vascular function.
Objective: We sought to determine whether an interaction between
cocoa flavanols and methylxanthines exists that influences cocoa
flavanol–dependent vascular effects.
Design: Test drinks that contained various amounts of cocoa flavanols
(0–820 mg) and methylxanthines (0–220 mg), either together or in-
dividually, were consumed by healthy volunteers (n = 47) in 4 differ-
ent clinical studies—3 with a randomized, double-masked crossover
design and 1 with 4 parallel crossover studies. Vascular status was
assessed by measuring flow-mediated vasodilation (FMD), brachial
pulse wave velocity (bPWV), circulating angiogenic cells (CACs),
and blood pressure before and 2 h after the ingestion of test drinks.
Results: Although cocoa flavanol intake increased FMD 2 h after
intake, the consumption of cocoa flavanols with methylxanthines
resulted in a greater enhancement of FMD. Methylxanthine intake
alone did not result in statistically significant changes in FMD.
Cocoa flavanol ingestion alone decreased bPWVand diastolic blood
pressure and increased CACs. Each of these changes was more
pronounced when cocoa flavanols and methylxanthines were in-
gested together. It is important to note that the area under the curve
of the plasma concentration of (2)-epicatechin metabolites over
time was higher after the co-ingestion of cocoa flavanols and meth-
ylxanthines than after the intake of cocoa flavanols alone. Similar
results were obtained when pure (2)-epicatechin and the methyl-
xanthines theobromine and caffeine were consumed together.
Conclusion: A substantial interaction between cocoa flavanols and
methylxanthines exists at the level of absorption, in which the
methylxanthines mediate an increased plasma concentration of
(2)-epicatechin metabolites that coincides with enhanced vascular
effects commonly ascribed to cocoa flavanol intake. This trial was
registered at clinicaltrials.gov as NCT02149238. Am J Clin Nutr
2017;105:352–60.
Keywords: cocoa flavanols,methylxanthines, cardiovascular function,
interaction, absorption
INTRODUCTION
Flavanols are plant-derived dietary bioactive compounds (1, 2)
that have gained increasing attention because of their beneficial
effects on human cardiovascular health, as demonstrated in short-
to medium-term clinical dietary intervention studies (3, 4).
Various controlled studies have demonstrated cocoa flavanol
(CF)7 intake–dependent improvements in endothelial function
and other markers of vascular function, including blood pressure
(BP), pulse wave velocity (PWV), and circulating angiogenic
cells (CACs) (5–8). CACs have been implicated in vascular
maintenance and repair and are a newly established biomarker
of cardiovascular risk (9). Furthermore, it has been shown that
the beneficial vascular effects observed after the consumption
of foods containing CFs can at least partly be attributed to
(2)-epicatechin (5, 10). However, in addition to flavanols, other
compounds present in foods that contain flavanol could poten-
tially affect vascular functions either by themselves or by
modulating flavanol-related effects. In this context, 2 of the most
important sources of flavanols in the diet—tea and cocoa-
derived products—contain substantial amounts of methylxan-
thines (5). The main methylxanthine in cocoa is theobromine,
whereas caffeine predominates in tea. However, smaller
1 Supported by European Union grant FP7-KBBE-2008-2B, Mars Inc.,
and the University of Du¨sseldorf. Mars Inc. was a scientific partner in
FLAVIOLA and provided the test drinks used in these studies.
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amounts of other methylxanthines can also be found in these
food products (11).
A rich data set exists that describes methylxanthine bioactivity
in humans, and several biological effects have been well de-
scribed (12, 13). In addition to the more commonly referenced
effects on the central nervous system, methylxanthines, partic-
ularly caffeine, have been demonstrated to directly modulate
vascular functions, including BP, arterial stiffness, and endo-
thelial function (14–16). In addition, co-ingestion can potentially
affect the absorption and plasma concentration of other com-
pounds. For instance, caffeine potentiates the analgesic and anti-
inflammatory actions of aspirin and increases absorption and
plasma concentration without influencing the volume of distri-
bution and clearance (17, 18). Thus, based on the presence of
both flavanols and methylxanthines in cocoa, we investigated the
potential role of methylxanthines as modulators of the cardio-
vascular effects of CFs in humans. We hypothesized that an
interaction between CFs and methylxanthines exists that mod-
ulates CF-dependent vascular effects. To investigate this hy-
pothesis, we performed 4 studies, each of which aimed to
answer a specific question.
METHODS
Subjects
Subjects for this study (NCT02149238) were recruited be-
tween 2011 February and 2014 December and consisted of
healthy young men aged 25–30 y. All subjects with symptoms of
cardiovascular disease, including coronary artery, peripheral
artery, or cerebrovascular disease; acute inflammation (C-reactive
protein .0.6 mg/dL); malignancies; arrhythmias (heart rhythm
other than sinus); arterial hypertension (systolic and diastolic
BP .140 and .90 mm Hg, respectively); diabetes (fasting
glucose .126 mg/dL); and hypercholesterolemia (total choles-
terol .200 mg/dL) were excluded.
Study design
Study protocol 1 was designed as the main proof-of-concept
study and aimed at assessing potential interactions of CFs and
methylxanthines with regard to the modulation of cardiovascular
function, including flow-mediated vasodilation (FMD) (first
endpoint), arterial stiffness, BP, and CACs (second endpoint).
To accomplish this, an acute 3-arm, single-center, random-
ized, double-masked crossover study (n = 12) was carried
out at Heinrich-Heine University Du¨sseldorf (HHUD). The
3 test drinks consumed by the volunteers provided CFs at
820 mg/75 kg body weight (BW) and cocoa methylxanthines at
125 mg/75 kg BW either together or individually. Table 1
shows the composition of the base powder used to reconstitute the
drinks. The total amount of CFs represents the sum of monomers
and oligomers (procyanidins) with a degree of polymerization
from 1 to 10. The predominant monomer in the test drinks was
(2)-epicatechin; the (2)-epicatechin content of the test drinks
was w112 mg/75 kg BW. All intake amounts were given on a
per 75-kg BW basis (for clarity, applied amounts are only pre-
sented as milligrams henceforth). On the 3 study days, which
were separated by a 1-wk washout, volunteers consumed the test
drinks, and cardiovascular functions were assessed before (0 h)
and 2 h (the time of peak FMD effects) after intake. Randomi-
zation and allocation to the 3 interventions were based on an
electronic treatment plan generated by a GraphPad web appli-
cation (www.graphpad.com; GraphPad Software Inc.).
Study protocol 2 aimed at assessing the effect of methylxan-
thines consumed with CFs at different intake amounts. To
accomplish this, a single-center (HHUD), randomized, double-
masked 4-arm study (n = 24; n = 6/group) was conducted. Sub-
jects were randomly assigned to the 4 parallel arms. In each arm,
volunteers were given test drinks that were consumed during the
10 (arms 1 and 2) or 8 (arms 3 and 4) different study visits
(crossover). The test drinks consisted of increasing amounts of
CFs (0, 102, 205, 410, and 820 mg) (arm 1); increasing amounts
of CFs (0, 102, 205, 410, and 820 mg) in the presence of 122 mg
methylxanthines (arm 2); increasing amounts of methylxanthines
(0, 61, 122, and 244 mg) (arm 3); and increasing amounts of
methylxanthines (0, 61, 122, and 244 mg) in the presence of
820 mg CFs (arm 4). Volunteers consumed the test drinks on the
study days, and FMD (first endpoint) measurements were taken
before (0 h) and 2 h after ingestion.
Study protocol 3 investigated how methylxanthines might
modulate the plasma concentration and urinary excretion of
the structurally related (2)-epicatechin metabolites (SREMs)
and the temporal association with FMD increases. This study
was conducted at HHUD and followed a randomized, double-
masked, 2-arm crossover design (n = 5). Volunteers were asked
to consume the test drinks on the study day, and blood and
0- to 24-h urine samples were collected following previously
described procedures (19). FMD (first endpoint) and blood
sample measurements were taken to determine SREMs (second
endpoint) and were performed before (0 h) and 1, 2, 3, 4, and
5 h after the ingestion of the test drink. The 2 test drinks
consumed by the volunteers contained 820 mg CFs, including
112 mg (2)-epicatechin, in either the absence or presence of
122 mg methylxanthines comprising 111 mg theobromine and
11 mg caffeine (Table 1).
TABLE 1
Composition of drink powder used to reconstitute the test drinks in study
protocols 1–31
CF + MX CF MX
Serving size, g/75 kg BW 13.2 13.2 13.2
(2)-Epicatechin, mg/75 kg BW 111.8 112.8 ND
(+)-Catechin, mg/75 kg BW 3.2 3.8 ND
(2)-Catechin, mg/75 kg BW 11.6 35 ND
(+)-Epicatechin, mg/75 kg BW ND ND ND
Total CFs, mg/75 kg BW 820 820 ND
Theobromine, mg/75 kg BW 111.0 1.6 112.8
Caffeine, mg/75 kg BW 11.4 1.2 10.2
Total MXs, mg/75 kg BW 122.4 2.8 123.0
Total calories, kcal/75 kg BW 35.4 34 37.4
Total fat, g/75 kg BW 0 0 0
Saturated fat, g/75 kg BW 0 0 0
Cholesterol, mg/75 kg BW 0 0 0
Total carbohydrates, g/75 kg BW 5.8 5.4 5.8
Sugars, g/75 kg BW 0 0 0
Protein, g/75 kg BW 0 0 0
Sodium, mg/75 kg BW 78 70 82
1BW, body weight; CF, cocoa flavanol; MX, methylxanthine; ND,
below limit of detection.
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Study protocol 4 assessed the effects of pure theobromine and
caffeine consumed simultaneously with (2)-epicatechin on
plasma concentrations (first endpoints) and the urinary excretion
of SREMs (second endpoint). To accomplish this, a single-center,
randomized, double-masked crossover study (n = 6) was carried
out at the University of California Davis, during which volunteers
consumed 75 mg (2)-epicatechin either with or without 400 mg
theobromine and 26 mg caffeine on 2 different days. On the study
day, blood samples were drawn before (0 h) and 1, 2, and 4 h after
the consumption of test drinks, and 0- to 24-h urine samples were
collected following previously described procedures (19).
In all studies, volunteers were asked to follow a low-flavanol
diet and to refrain from consuming alcohol, coffee, or other
beverages that contain caffeine on the day before and during the
study visits. Volunteers were also asked to fast for 12 h before
each study day (water ad libitum). Study visits were scheduled
$1 wk apart to avoid potential carryover effects. The study
protocols were approved by the HHUD ethics committee and the
University of California Davis institutional review board; all
volunteers gave written informed consent.
Test drinks containing CFs and methylxanthines
Specifically designed test drinks that contained CFs and
methylxanthines either together or individually were used in all
studies. The amount of test drinks consumed was standardized
on a per 75-kg BW basis, and regardless of the amount of CFs and
methylxanthines, all test drinks used in the same study contained
similar macro- and micronutrients, as well as very similar oro-
sensory and physicochemical characteristics.
The test drinks used in study protocols 1–3 consisted of fruit-
flavored nondairy drinks that contained CFs and the methylxan-
thines theobromine and caffeine either individually or together
(Table 1). These test drinks were prepared for a 75-kg subject by
reconstituting 13.2 g of a drink powder with 500 mL water to
achieve a content of 820 mg CFs and/or 122 mg methylxanthines.
Other intake amounts were achieved with the use of more or less
of the identical drink powders in 500 mL water (e.g., 6.6 g to
achieve 410 mg CFs). The source of CFs and methylxanthines in
the test drinks that contained both groups of compounds simul-
taneously consisted of a standardized cocoa extract manufactured
with the use of the Cocoapro process (Mars Inc.).
To prepare the drinks provided in study protocol 4, we used
food-grade (2)-epicatechin isolated from cocoa (Mars Inc.);
food-grade theobromine (AHD International LLC) and caf-
feine (Perrigo) were added to milk (1% fat) as a vehicle for
delivering these compounds. The final composition of the test
drinks was as follows: 75 mg (2)-epicatechin, 400 mg theo-
bromine, and 26 mg caffeine dissolved in 375 g milk and
75 mg (2)-epicatechin dissolved in 375 g milk.
FMD assessment
FMD was measured as previously described (7). Briefly, the
diameter and flow velocity of the brachial artery was measured
with the use of a Vivid I 10-MHz transducer (General Electric) and
automatic edge-detection software (Brachial Analyzer version 5;
Medical Imaging Applications) that yielded SDs of mean differ-
ences between repeated measurements of ,1%. The brachial
artery diameter was measured 2 cm proximal to the elbow.
Reactive hyperemia was induced by 5 min of distal lower-arm
occlusion with a sphygmomanometric cuff inflated to
250 mm Hg. After cuff deflation (20, 40, 60, and 80 s), the
diameter was assessed, and the FMD was calculated as the
maximal relative diameter gain relative to the baseline.
Sublingual nitroglycerin (0.4 mg) was administered, and
endothelium-independent nitroglycerin-mediated dilation was
assessed at 4 min. The FMD was expressed as (diametermax 2
diameterbaseline)/diameterbaseline 3 100.
FMD was defined as the primary outcome (studies 1–3); thus,
power calculations were based on FMD. The intra- and in-
terindividual variability for FMD measurements established in
our laboratory are 0.9% (SDs of differences between repeated
FMD measurements in 20 healthy subjects) (C Heiss, unpub-
lished results, 2015) and 1% (SDs within a group of healthy
subjects), respectively. Therefore, a crossover study with 12, 6,
or 5 subjects receiving treatments on 2 separate days would
provide sufficient power to detect an absolute change in FMD of
0.8%, 1.3%, or 1.5% (2-sided a = 0.05; power = 0.80). For
parallel independent group comparisons in study 2, 6 subjects
receiving different treatments would provide sufficient power
to detect absolute differences in FMD mean values of 1.8%
(2-sided a = 0.05; power = 0.80).
Arterial stiffness assessment
Arterial stiffness was determined by assessing the brachial
PWV (bPWV) before and 2 h after administering the test
drinks in study 1. The bPWV was calculated by dividing the
distance between the suprasternal notch to the cubital fossa
by the pulse transit time. The pulse transit time from the heart
to the brachial artery was calculated as the time delay between
the R wave on an electrocardiogram and the beginning of the
systolic Doppler flow velocity taken during brachial artery
ultrasound exams. The distance between the suprasternal notch
via the shoulder to the cubital fossa was determined with
measuring tape.
BP measurements
Office BP was measured in study 1 before and 2 h after ad-
ministering the test drinks in study 1 with the use of an automated
clinical digital sphygmomanometer (Dynamap) at the upper left arm
in the supine position after 10 min of rest in a quiet room with the
arm at heart level before blood was drawn and FMD was measured.
We took 3 measurements and discarded the first and calculated the
mean values for the second and third for further analysis.
CAC quantification with the use of flow cytometry
CACs were isolated and quantitated with the use of flow
cytometry as described previously (20). Briefly, blood was drawn
in study 1 in heparinized vacutainer tubes before and 2 h after the
ingestion of the 3 drinks, and the number of CACs in whole blood
was measured as CD34/kinase insert domain receptor (KDR)
double-positive cells with the use of flow cytometry. Staining was
performed after washing with phosphate-buffered saline (PBS)
and Fc receptor blocking (Ig: 1 mg/mL; Zymed). Phycoerythrin
(CD34) and allophycocyanin (KDR)-conjugated anti-human
mouse antibodies (Pharmingen) or isotype controls were in-
cubated with a 100-mL (106-mL) cell suspension with the use
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of a fluorescence-activated cell-sorting buffer (1% bovine serum
albumin/PBS) for 20 min. After lysing red blood cells and washing
with the fluorescence-activated cell-sorting buffer twice, cells
were fixed with 1% formaldehyde/PBS and stored at 48C until
analysis; 100,000 events were collected in the lymphocyte and
monocyte gates (FACSCanto; Becton Dickinson).
Quantification of (2)-epicatechin metabolites in plasma
and urine
The quantification of SREMs corresponding to the sum of
sulfated, glucuronidated, and O-methylated (2)-epicatechin
metabolites was assessed in plasma and urine with the use of
HPLC. Samples were analyzed with the use of a reversed-phase
chromatograph equipped with a 4.6-mm Luna C18 column
(3-mm particle size; Phenomenex) and a Hewlett-Packard
1200-series chromatograph equipped with a fluorescence detector
operating at 276 nm (excitation) and 316 nm (emission) as
described previously (19). Authentic reference SREMs were
provided by Mars Inc.
As published previously (21), the intraindividual variability in
the peak plasma concentration (Cmax) and 0- to 6-h AUC (AUC0–6 h)
of total SREMs was 16% and 17%, respectively. The in-
terindividual variability in the AUC0–6 h and Cmax of total
SREMs was 38% and 39%, respectively. Plasma concentra-
tions of SREMs were defined as the primary outcome of study
4; therefore, power calculations were based on SREMs. The
intraindividual variability for the Cmax of total SREMs estab-
lished in our laboratory was 200 nmol/L (SDs of differences
between repeated SREM measurements after acute consump-
tion of identical drinks containing 10.3 mg/kg BW of CFs in
7 healthy subjects) (21). Therefore, our crossover studies with
6 subjects who received treatments on 2 separate days provided
sufficient power to detect an absolute change in SREMs of
285 nmol/L (2-sided a = 0.05; power = 0.80).
Statistical analyses
Results are expressed as means 6 SDs. Groups were com-
pared with the use of 2-factor repeated-measures ANOVA, and,
if significant, a consecutive Bonferroni post hoc test was per-
formed. The ANOVA in studies 1, 3, and 4 had the 2 within-
subject factors (time and treatment). In study 2, we compared
the changes in FMD at 2 h with the baseline between treatments.
We performed 2 separate mixed-model 2-factor ANOVAs with
1 within-subject factor (methylxanthines: 0, 61, 122, and
244 mg; CFs: 0, 102, 205, 410, and 820 mg) and 1 between-
subject factor (methylxanthines: 0 and 122 mg; CFs: 0 and
820 mg). Linear relations between continuous variables were
expressed as Pearson’s r. P # 0.05 was considered statistically
significant. Statistical analyses were performed with the use of
SPSS version 19 (IBM). Intake amount–response relations were
analyzed with the use of a nonlinear curve fit with Graph Pad
Prism 6, and intake amounts of zero were arbitrarily set to 1.
RESULTS
Baseline characteristics of study groups
The overall study population consisted of 47 young and
healthy men. Figure 1 shows the Consolidated Standards of
Reporting Trials study flow diagram, distribution of subjects to
studies, and individual study protocols. The characteristics of
the study population are summarized in Table 2. No significant
differences were observed between the volunteers in the in-
dividual studies, and all drinks were well tolerated. No adverse
effects or side effects were observed in any of the studies.
Methylxanthines increase the effects of CFs on vascular
biomarkers (study 1)
Study protocol 1 investigated whether the co-administration of
methylxanthines and CFs would modulate CF-related effects on
established biomarkers of vascular function, including FMD,
BP, PWV, and CACs. The results showed that the ingestion of both
test drinks containing CFs resulted in a significant increase in FMD
2 h after intake compared with the baseline (Figure 2A). Fur-
thermore, the increase in FMD after the intake of the test drink
containing both CFs and methylxanthines was greater than after
the intake of the drink containing only CFs (1.7% 6 0.6%
compared with 0.8% 6 0.3%, respectively; P , 0.05). No
changes in FMD were observed with the intake of the test drink
containing methylxanthines only (0.1% 6 0.5%). No statistically
significant difference in nitroglycerin-mediated dilation at the end
of each study visit was observed (after CF intake: 14.6%6 1.0%;
FIGURE 1 Study flow (CONSORT diagram) (A) and schematics of
study protocols (B). BL, baseline; BW, body weight; CF, cocoa flavanol;
CONSORT, Consolidated Standards of Reporting Trials; HHUD, Heinrich-
Heine University Du¨sseldorf; MX, methylxanthine; UCD, University of
California Davis.
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CF and methylxanthine intake: 14.6% 6 2.5%; methylxanthine
intake: 14.2%6 1.0%; P = 0.421), demonstrating that none of the
test drinks changed the endothelium-independent vasodilation
response.
In addition to FMD, bPWV, BP, and the number of CACs were
assessed. Only the ingestion of the test drink containing CFs
resulted in significant changes in CD34+/KDR+ CACs (5 6 4-
fold increase; P , 0.001) as well as bPWV (20.26 6 0.14 m/s;
P = 0.011), with no effect on diastolic BP (22 6 6 mm Hg;
Figure 2B–D). The consumption of the test drink containing CFs
and methylxanthines together also resulted in positive changes
in CD34+/KDR+ CACs (12 6 4-fold; P , 0.001) and decreased
bPWV (20.46 6 0.22 m/s; P = 0.011) and diastolic BP (26 6
4 mm Hg; P = 0.011). Similar to the findings on FMD, however,
the magnitude of the changes on CD34+/KDR+ CACs, bPWV,
and diastolic BP after the intake of CFs and methylxanthines
simultaneously were greater than after the intake of only CFs.
No significant changes in the vascular parameters were observed
after the intake of the test drink containing only methylxan-
thines. Systolic BP and heart rate were not significantly affected
by the ingestion of any of the test drinks. In summary, the intake
of CFs acutely improved multiple functional markers of vascular
health, and, notably, the co-ingestions of CFs with methylxan-
thines enhanced the effect of CFs on the vascular function
biomarkers investigated, namely FMD, CACs, bPWV, and di-
astolic BP.
Intake amount dependence of interaction between
methylxanthines and CFs (study 2)
Study protocol 2 investigated changes in FMD after the intake
of test drinks containing a range of intake amounts of CFs and
methylxanthines. Volunteers who consumed increasing amounts
of CFs (n = 6) showed a significant intake amount–dependent
increase in FMD 2 h after the intake of.105 mg compared with
the baseline (Figure 3A). This increase in FMD depended on
the amount of CFs consumed, with a maximal FMD increase
(DFMDmax) of 1.4% (95% CI: 1.2%, 1.7%) after 820 mg and an
intake amount to achieve a half-maximal increase (ED50) of
199 mg (95% CI: 150, 264 mg; R2 = 0.87).
When volunteers consumed test drinks with increasing
amounts of CFs in conjunctionwith 122mgmethylxanthines (n= 6),
there was a CF intake–dependent increase in FMD 2 h after intake,
with a DFMDmax of 2.5% (95% CI: 1.9%, 3.1%) after the ingestion
of 820 mg CFs and an ED50 of 226 mg (95% CI: 152, 335 mg;
FIGURE 2 Impact of MXs on CF-related improvements in vascular param-
eters. (A) FMD at 0 and 2 h after the ingestion of the test drinks; (B) mobilization
of CD34+/KDR+ CACs; (C) bPWV; and (D) SBP and DBP. Columns are mean
values and error bars are SDs. Green columns show the drink containing CF only,
blue columns show the drink containing MX only, and red columns show the
drink containing both CF and MX (n = 12; 2-factor repeated-measures ANOVA;
P , 0.01 for time-by-treatment interaction for all parameters). *P , 0.05 com-
pared with respective baseline (0 h). #P , 0.05 compared with respective time
point after CF. BP, blood pressure; bPWV, brachial pulse wave velocity; CAC,
circulating angiogenic cell; CF, cocoa flavanol; DBP, diastolic blood pressure;
FMD, flow-mediated vasodilation; KDR, kinase insert domain receptor; MNC,
mononuclear cell; MX, methylxanthine; SBP, systolic blood pressure.
TABLE 2
Characteristics of study population1
Values
Men, n 47
Age, y 25.1 6 2.3
BMI, kg/m2 24.8 6 2.8
Creatinine, mg/dL 0.9 6 0.1
Smokers, n 5
Fasting glucose, mg/dL 89 6 4
Total cholesterol, mg/dL 172 6 25
Heart rate, beats/min 60 6 8
SBP, mm Hg 121 6 11
DBP, mm Hg 74 6 9
1All values are means6 SDs unless otherwise indicated. DBP, diastolic
blood pressure; SBP, systolic blood pressure.
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R2 = 0.84) (Figure 3A). In this context, DFMDmax in the group that
consumed CFs and methylxanthines together was significantly
greater than the DFMDmax attained after the intake of a same
amount of CFs without methylxanthines. However, no significant
differences were observed between the ED50 of CFs when con-
sumed with or without methylxanthines.
The next test was to determine whether the intake of meth-
ylxanthines alone can improve FMD. The results showed that no
changes in FMD in the group that consumed methylxanthines
only (n = 6) in amounts #244 mg (Figure 3B). However, when
the subjects consumed 820 mg CFs in combination with in-
creasing amounts of methylxanthine, this resulted in a methyl-
xanthine intake–dependent increase in FMD, with a DFMDmax
of 2.8% (95% CI: 1.7%, 3.8%) after 244 mg methylxanthines
and an ED50 of 80 mg (95% CI: 40, 160 mg; R
2 = 0.67) (Figure
3B). The baseline FMD values at 0 h were not significantly
different between the groups.
Methylxanthine intake increases CF-related FMD
improvements concomitant with increased plasma
concentrations of SREMs (study 3)
The consumption of CFs with and without methylxanthines
(study 3) significantly increased the FMD response, with a
maximal FMD response 2 h after intake in both groups (Figure
4A). In keeping with the results of the previous sections, the
FMD response in study protocol 3 was significantly greater
when CFs were consumed with methylxanthines. In addition to
the improvements in FMD, the ingestion of the test drink con-
taining both CFs and methylxanthines resulted in a significantly
higher Cmax of SREMs than after the ingestion of the test drink
containing only CFs (Figure 4B). The AUC0–5 h of plasma
concentration over time after the intake of the test drink con-
taining CFs and methylxanthines was 37% 6 17% higher
than the analog AUC0–5 h after the intake of the drink con-
taining CFs only (7.2 6 1.9 compared with 10.9 6 1.2 mmol/h;
P = 0.007). No differences in the amount of SREMs excreted in
the 0- to 24-h urine samples were observed after the intake of
either drink (8.6 6 1.4 compared with 8.2 6 2.7 mmol; P . 0.05
for the test drinks that contained CFs and methylxanthines
compared with the test drink that contained CFs alone).
The effects of theobromine and caffeine on plasma SREM
concentrations after the intake of (2)-epicatechin (study 4)
Results similar to study 3 were obtained when applying study
protocol 4, in the context of which CFs and methylxanthines were
provided in a cocoa-free formulation that emulated the com-
position of naturally occurring cocoa with respect to its content of
(2)-epicatechin, theobromine, and caffeine. The consumption of
the test drinks containing either (2)-epicatechin alone and a
combination of (2)-epicatechin and theobromine and caffeine
significantly increased the SREM Cmax, with maximal values 2 h
after intake (Figure 4C). Consistent with data from study pro-
tocol 3, a higher SREM Cmax was detected after the consump-
tion of the test drink containing theobromine and caffeine
and (2)-epicatechin than with the Cmax attained after the intake
of the test drink containing only (2)-epicatechin (P , 0.005).
The plasma AUCs of SREM concentrations compared with the
time for #4 h (AUC0–4 h) after the intake of the test drink
containing (2)-epicatechin and theobromine and caffeine was
22% 6 5% higher than the AUC0–4 h after the intake of the
drink containing (2)-epicatechin only (1.43 6 0.22 compared
with 1.76 6 0.40 mmol/h; P = 0.014). No differences in the
amount of SREMs excreted in the 0- to 24-h urine samples were
observed after the intake of either drink [10.8 6 2.1 compared
with 11.1 6 2 0.1 mmol; P . 0.05 for the test drink containing
(2)-epicatechin and theobromine and caffeine compared with
(2)-epicatechin only].
DISCUSSION
The intake of test drinks containing CFs either with or without
methylxanthines resulted in acute improvements of established
functional cardiovascular biomarkers in healthy adults, namely
FMD, CAC, PWV, and diastolic BP. These findings are in
agreement with previous studies that have reported beneficial
vascular effects after the intake of CFs or foods containing fla-
vanols (7, 8). In contrast, the intake of methylxanthines alone did
not mediate acute changes in the biomarkers assessed herein.
Although the consumption of methylxanthines has been reported
to modulate certain vascular parameters (15, 22), it is plausible
that the amounts of methylxanthines administered herein or the
FIGURE 3 Intake-dependent interactions between CFs and MXs. (A) Potentiation of FMD response at 2 h after the ingestion of increasing amounts of
CFs alone (102, 205, 410, and 820 mg/kg BW; green line) and co-administered with a fixed amount of MXs (122 mg/kg BW; red curve). (B) The blue line
shows that FMD values remained unchanged at 2 h after the ingestion of increasing amounts of MXs (0, 61, 122, and 244 mg/kg BW); the red line shows FMD
values when a fixed amount of CFs (820 mg/kg BW) was co-administered. Symbols are mean values and error bars are SDs (n = 24; 2-factor mixed-model
ANOVA; P , 0.01 for time-by-treatment interaction for all parameters). *P , 0.05 compared with respective 0-mg amount. #P , 0.05 compared with the
value of the other group. BW, body weight; CF, cocoa flavanol; FMD, flow-mediated vasodilation; MX, methylxanthine.
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matrix in which they were consumed were not conducive for
mediating the effects on the observed parameters. When CFs and
methylxanthines were ingested simultaneously, as occurs nor-
mally in the context of cocoa that contains CFs, changes over the
baseline in FMD, CACs, and PWV of 47%, 42%, and 57%,
respectively, were observed, indicating the existence of a syn-
ergistic mode of action. The results of study 2 confirmed these
findings and further proved that this synergistic effect depended
on the amount of CFs and methylxanthines consumed. An im-
portant consequence of this synergism is that it may explain to a
certain degree the variability in the magnitude of effects observed
in different studies with test materials containing varying
amounts of CFs and methylxanthines (23). In this context, we and
others have shown that the intake of pure (2)-epicatechin can
acutely improve endothelial function after the consumption of
1–2 mg/kg BW (5, 10). It is important to note that the effect size
of (2)-epicatechin intake observed herein was smaller than an
earlier study (5) in which the test drink contained both CFs and
methylxanthines.
A recent study on the effects of (2)-epicatechin intake (24)
did not detect statistically significant long-term changes in
FMD. It may be that investigations that use a purified dietary
constituent do not fully mimic the effects or effect sizes ob-
served when the same constituent is consumed in its native
food or food matrix. Our data demonstrate that the effect of
(2)-epicatechin intake–related changes in vascular function is
greater when the flavanol is consumed with methylxanthine,
similar to the consumption of (2)-epicatechin as part of certain
teas or cocoas.
These data indicate that methylxanthines, when consumed
together with CFs, lead to significantly higher concentrations of
plasma SREMs without affecting excretion. These findings
confirm previous results in rats that suggested that theobromine
intake increases the absorption of (2)-epicatechin (12, 25). A
similar pattern is observed when aspirin is consumed together
with caffeine (18). Potential mechanisms by which methylxan-
thines may increase (2)-epicatechin (or aspirin) absorption are
unknown but may include specific effects on gastrointestinal
physiology (e.g., motility and/or secretion, blood flow, gastric
pH) or even the modulation of transporters that regulate the
efflux of SREMs in the gut. The fact that cocoa methylxanthines
and theobromine and caffeine increased the concentration of
SREMs in plasma compared with the concentration that would
be reached when CFs or pure (2)-epicatechin were consumed
alone may explain how cocoa methylxanthines may enhance the
vascular effects of CFs. However, methylxanthines are com-
pounds that could also interact with CF effects at a biochemical
level via the modulation of biological effector processes.
Methylxanthines have been reported to act on adenosine re-
ceptors and are phosphodiesterase inhibitors (26, 27). These
molecular actions may also provide a feasible explanation for a
synergistic effect of CFs and methylxanthines at the level of
CACs, diastolic BP, FMD, and PWV. However, because the
mechanisms of action of CFs have not yet not been fully elu-
cidated, it is difficult to ascertain whether the effect of methyl-
xanthines on adenosine receptors and phosphodiesterase activity
are related to the CF-methylxanthine interactions that modulate
the vascular effects observed herein or whether there are still
other molecular targets yet to be identified. Thus, future studies
are needed to fully understand CF-methylxanthine interactions
and the potential molecular events that mediate the observed
synergies on the level of vascular function.
The methylxanthines in cocoa are composed predominantly
of theobromine, with only small amounts of caffeine (110 mg
theobromine and 10 mg caffeine). However, dietary flavanols are
also found in other food sources in which the predominant
methylxanthine is caffeine, as is the case for tea, which represents
the largest contributor of flavanols in the European diet (1). In this
context, it is pertinent to ask whether the findings presented in this
study can be extrapolated to circumstances in which flavanols
are co-ingested with other types of methylxanthines, particu-
larly caffeine. Previous studies have suggested that theobro-
mine and caffeine may have different potencies when mediating
FIGURE 4 Time course of endothelial function (FMD) (A) and SREMs
(B) in plasma after the ingestion of CFs (green lines) alone or co-ingested
with MXs (red lines). (C) Time course of SREMs in plasma after the intake
of (2)-epicatechin alone (green line) or (2)-epicatechin and theobromine
and caffeine (red line). Symbols are mean values and error bars are SDs
[n = 5 for study 3 and n = 6 for study 4; 2-factor repeated-measures
ANOVA; P = 0.0004 (A), P = 0.0052 (B), and P = 0.004 (C) for time-
by-treatment interactions]. *P , 0.05 compared with respective baseline at
0 h. #P , 0.05 compared with respective CF or (2)-epicatechin adminis-
tration. CF, cocoa flavanol; FMD, flow-mediated vasodilation; MX, meth-
ylxanthine; SREM, structurally related (2)-epicatechin metabolite.
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a given effect (12, 28). With regard to BP, BP-lowering and
BP-increasing effects have been reported for theobromine and
caffeine, respectively. In healthy volunteers, the intake of 700 mg
theobromine decreased BP acutely, whereas 120 mg caffeine
increased BP (12). Other studies have suggested that caffeine
may adversely affect arterial stiffness (14, 29), whereas the
consumption of chocolate containing theobromine did not show
any effect on arterial stiffness (30, 31). Thus, the extrapolation of
our findings to foods other than cocoa, including green and black
teas, requires further investigation.
We investigated the vascular effects after the intake of CFs and
methylxanthines under conditions in which these substances were
either ingested together or individually and in amounts that
ranged between 0 and 820 mg for CFs and 0 and 220 mg for
methylxanthines. The intake amount ranges investigated in this
study encompass the daily intake amounts observed in population-
based assessments (1) and are thus relevant in the context of
nutrition. The key findings were as follows: 1) CF-mediated
vascular effects were enhanced when CFs were co-ingested
with methylxanthines, whereas the ingestion of cocoa meth-
ylxanthines alone did not result in significant effects on the
assessed biomarkers of vascular function; 2) the modulation
of CF-related vascular effects by the co-ingestion of methyl-
xanthines depended on the relative amount of CFs and methyl-
xanthines consumed; and 3) the co-ingestion of CFs and
methylxanthines resulted in a significantly higher SREM Cmax
and AUC of the plasma concentration over time than CF intake
alone. Taken together, our results demonstrate a significant in-
teraction between cocoa methylxanthines and CFs in which
methylxanthines, likely by affecting CF absorption, enhance the
vascular effects commonly ascribed to CF intake with cocoa.
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